Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
PMID: 42530945
Geriatric Oral Health in the United States: Current Status and Challenges.
Geriatric Oral Health in the United States: Current Status and Challenges. Geriatrics (Basel). 2026 Jul 13; 11(4).
PMID: 42496350
Multi-modal AI for comprehensive breast cancer prognostication.
Multi-modal AI for comprehensive breast cancer prognostication. Nat Commun. 2026 May 20; 17(1).
PMID: 42161927
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence. medRxiv. 2026 May 12.
PMID: 42180367
Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images.
Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images. NPJ Breast Cancer. 2026 May 11; 12(1).
PMID: 42115215
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer.
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer. medRxiv. 2026 May 05.
PMID: 42078387
Oral Health Care in the United States.
Oral Health Care in the United States. Dent J (Basel). 2026 May 02; 14(5).
PMID: 42187643
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study. Lancet Oncol. 2026 Apr; 27(4):512-526.
PMID: 41831466
Advancing healthcare AI governance through a comprehensive maturity model based on systematic review.
Advancing healthcare AI governance through a comprehensive maturity model based on systematic review. NPJ Digit Med. 2026 Feb 11; 9(1).
PMID: 41673321
Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ.
Trends in Nonsurgical Management for Low-Risk, Hormone Receptor-Positive Ductal Carcinoma In Situ. JAMA Netw Open. 2026 02 02; 9(2):e2558248.
PMID: 41665902